BRAF-mutant mCRC phase III trial initiated
Merck partners with Array BioPharma and Pierre Fabre
06-Jun-2016 -
Merck announced with Array BioPharma Inc. and Pierre Fabre, the initiation of a prospective, randomized, global Phase III clinical trial of BRAF-mutant metastatic colorectal cancer (mCRC), investigating a new combination of Erbitux (cetuximab), a standard-of-care treatment for RAS wild-type mCRC, ...
Binimetinib
cetuximab
colorectal cancer
+3